Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENETACIBLE: Venetoclax Plasma Dosage in AML
NCT06030089Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Feb 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Plasmatic dosage of Venetoclax at 12 months. Started Feb 2024; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06030089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06030089.